Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2011-06-10 | Mr. Lundy has more than 20 years of experience in drug and diagnostic product development and commercialization. He was Chief Executive Officer of MicroPhage from 2008 to 2010. Mr. Lundy was Senior VP of sales and marketing for Vermillion from 2007 to 2008. Mr. Lundy joined Vermillion from GeneOhm (2003-2007), a division of Becton, Dickinson and Company Diagnostics, where he served as Vice President of Sales and Marketing. At GeneOhm, Mr. Lundy successfully led the commercial launch of several novel molecular diagnostic assays including the first molecular test for Methicillin Resistant Staphylococcus Aureus. From 2002 to 2003, Mr. Lundy served as Vice President of Marketing for Esoterix, Inc., which was acquired by Laboratory Corporation of America, and led the commercial integration and re-branding of the numerous reference labs acquired by Esoterix. Prior to Esoterix, he served as Marketing Director for Molecular Diagnostics and Critical Care Testing at Bayer Diagnostics Corporation. Mr. Lundy graduated from the United States Air Force Academy with a Bachelor of Science and was an officer with the United States Air Force from 1983 to 1988. |
| 2012-04-09 | Mr. Lundy has more than 20 years of experience in drug and diagnostic product development and commercialization. He most recently was Chief Executive Officer of MicroPhage from 2008 to 2010. Mr. Lundy was Senior VP of sales and marketing for Vermillion from 2007 to 2008. Mr. Lundy joined Vermillion from GeneOhm (2003-2007), a division of Becton, Dickinson and Company Diagnostics, where he served as Vice President of Sales and Marketing. |
| 2012-10-15 | Stephen T. Lundy, Chief Executive Officer and President; no mention of technical or software skills, primarily executive compensation and stock options. |
| 2013-04-29 | Mr. Lundy graduated from the United States Air Force Academy with a B.S. degree and was an officer with the United States Air Force from 1983 to 1988. |
| 2014-04-30 | Mr. Lundy has more than 25 years of experience in medical and diagnostic product development and commercialization. He graduated from the United States Air Force Academy with a B.S. degree. |
| 2015-07-24 | Mr. Lundy has more than 25 years of experience in medical and diagnostic product development and commercialization. He graduated from the United States Air Force Academy with a B.S. degree and was an officer with the United States Air Force from 1983 to 1988. |
| 2016-02-29 | Stephen T. Lundy (1) Includes 4,000 shares directly owned. Also includes options to purchase 7,057 shares at $68.40 per share, options to purchase 2,073 shares at $17.70 per share, options to purchase 11,195 shares at $20.40 per share, options to purchase 12,500 shares at $3.96 per share, options to purchase 99,336 shares at $2.10 per share, options to purchase 137,000 shares at $2.04 per share, options to purchase 178,000 shares at $2.27 per share and options to purchase 151,000 shares at $1.89 per share. |
| 2016-10-17 | Mr. Lundy has more than 25 years of experience in medical and diagnostic product development and commercialization. He graduated from the United States Air Force Academy with a B.S. degree and was an officer with the United States Air Force from 1983 to 1988. |
Data sourced from SEC filings. Last updated: 2026-02-03